Healthcare
Kyverna Therapeutics, Inc.(KYTX)
Live Price
Offline$7.90
+0.38% today
1Y Change
+128.24%
Window
Jun 26, 2025 โ Jun 16, 2026
- Market Cap
- $380.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -9.3%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 26, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Kyverna Therapeutics, Inc. (KYTX) is a Healthcare stock with a market cap of $380.00M and listed on NASDAQ. The stock last traded around $7.90 and up 128.2% across the available one-year price window (Jun 26, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -9.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -9.3%, free cash flow -32.0% with operating margin 0.0% and ROIC -65.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines KYTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -9.3%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +2.6% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +5.4% | -15.0% | -25.1% |
2026 Mar 26, 2026 | +5.3% | -2.9% | +10.5% | +12.8% |
2025 Nov 12, 2025 | +12.4% | -11.6% | +12.3% | +14.1% |
Benchmark Edge
KYTX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KYTX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KYTX Max Drawdown
-36.14%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KYTX and SPY.
Company Overview
Kyverna Therapeutics, Inc.
NASDAQ Global Select
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
- Leadership
- Warner Biddle
- IPO Date
- Feb 9, 2024
- Employees
- 112
- Street Address
- 5980 Horton Street
- Mailing
- Emeryville, CA, 94608
- Region
- Emeryville, CA, US
- Reporting Currency
- USD
- Investor Line
- (510) 925-2492
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.8
Growth
- Revenue
- 0.0%
- EPS
- -9.3%
- Free Cash Flow
- -32.0%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -81.4%
- ROIC
- -65.0%
Balance Sheet
- Debt/Equity
- 0.12
- Current Ratio
- 7.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.